Radium 223 dichloride for prostate cancer treatment

Emmanuel Deshayes (1, 2) , Mathieu Roumiguié (3) , Constance Thibault (4) , Philippe Beuzeboc (5) , Florent Cachin (6, 7) , Christophe Hennequin (8, 9) , Damien Huglo (10, 11) , François Rozet (12) , Diana Kassab-Chahmi , Xavier Rebillard (13, 14) , Nadine Houédé (15, 1, 16)

1 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier
2 ICM - Institut régional de Cancérologie de Montpellier
3 Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse]
4 HEGP - Hôpital Européen Georges Pompidou [APHP]
5 Department of Medical Oncology
6 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]
7 IMoST - Imagerie Moléculaire et Stratégies Théranostiques
8 SU - Sorbonne Université
9 AP-HP - Hopital Saint-Louis [AP-HP]
10 Thiais - Therapies Interventionnelles Assistees Par l'Image et la Simulation - U 703
11 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
12 Service d'Oncologie Médicale [Montsouris]
13 Clinique Beau Soleil [Montpellier]
14 IBMM - Institut des Biomolécules Max Mousseron [Pôle Chimie Balard]
15 Institut Bergonié [Bordeaux]
16 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes

Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo®) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223 dichloride is a calcium-mimetic agent that specifically targets bone lesions. Radium-223 dichloride has been approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases, without known visceral metastases. In this review, first we summarize the interplay between prostate tumor cells and bone microenvironment; then, we discuss radium-223 dichloride mechanism of action and present the results of the available clinical trials and future developments for this new drug.

Mots clés: agents; bone metastasis; development; drug; mCRPC; mechanism

Domaines: Sciences du Vivant [q-bio]

Emmanuel Deshayes, Mathieu Roumiguié, Constance Thibault, Philippe Beuzeboc, Florent Cachin, et al.. Radium 223 dichloride for prostate cancer treatment. Drug Design, Development and Therapy, 2017, Volume 11, pp.2643 - 2651. ⟨10.2147/DDDT.S122417⟩. ⟨hal-01657891⟩